Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo
Express Scripts
Baxter
Teva
Federal Trade Commission
US Army
Citi
US Department of Justice
AstraZeneca

Generated: October 21, 2017

DrugPatentWatch Database Preview

STALEVO 200 Drug Profile

« Back to Dashboard

What is the patent landscape for Stalevo 200, and what generic Stalevo 200 alternatives are available?

Stalevo 200 is a drug marketed by Orion Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-six patent family members in forty countries.

The generic ingredient in STALEVO 200 is carbidopa; entacapone; levodopa. There are eighteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the carbidopa; entacapone; levodopa profile page.

Summary for Tradename: STALEVO 200

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list6
Bulk Api Vendors: see list1
Clinical Trials: see list3,558
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:STALEVO 200 at DailyMed

Pharmacology for Tradename: STALEVO 200

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orion Pharma
STALEVO 200
carbidopa; entacapone; levodopa
TABLET;ORAL021485-004Aug 2, 2007ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Orion Pharma
STALEVO 200
carbidopa; entacapone; levodopa
TABLET;ORAL021485-004Aug 2, 2007ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: STALEVO 200

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Orion Pharma
STALEVO 200
carbidopa; entacapone; levodopa
TABLET;ORAL021485-004Aug 2, 2007► Subscribe► Subscribe
Orion Pharma
STALEVO 200
carbidopa; entacapone; levodopa
TABLET;ORAL021485-004Aug 2, 2007► Subscribe► Subscribe
Orion Pharma
STALEVO 200
carbidopa; entacapone; levodopa
TABLET;ORAL021485-004Aug 2, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for STALEVO 200

Drugname Dosage Strength RLD Submissiondate
carbidopa, levodopa and entacaponeTablets50 mg/200 mg/200 mgStalevo 2008/28/2008

International Patent Family for Tradename: STALEVO 200

Country Document Number Estimated Expiration
Czech Republic303010► Subscribe
China1358090► Subscribe
Czech Republic20014636► Subscribe
TaiwanI241187► Subscribe
Israel146807► Subscribe
France2797587► Subscribe
Peru03992001► Subscribe
Norway20110090► Subscribe
Japan4204783► Subscribe
Denmark1189608► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Citi
Dow
Teva
AstraZeneca
US Army
Fish and Richardson
Boehringer Ingelheim
Baxter
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot